HD-PLC-ALLIANCE
In order to integrate the latest improvements in speed and range of the HD-PLC*1 technology promoted by HD-PLC Alliance*2 , the Alliance has proposed the specifications of the next generation technology to the IEEE Standards Association*3 . To the great satisfaction of the Alliance members, recently published IEEE 1901-2020 Standard includes the latest HD-PLC features that provide higher speed, longer range wired communications over existing metal wires (control cable, coaxial cable, power cable, etc.).
Compared with wireless communication systems, HD-PLC enables more secure, stable and reliable communications. Furthermore, the use of existing cables allows a network infrastructure to cover not only indoors such as homes, buildings and factories but also outdoors extending several kilometers.
Mr. Yoshiyuki Miyabe, Senior Adviser of HD-PLC Alliance and Senior Managing Executive Officer of Panasonic Corporation, has sent a message, “Our company and HD-PLC Alliance have developed the HD-PLC technology cooperatively, which is now published as IEEE 1901-2020 standard. We anticipate this standardization will help make HD-PLC a breakthrough technology for the coming era of IoT. Making the most of this result for various products and business solutions for the future, we endeavor to further support innovation and advancement of the technology to provide new values to our customers.”
HD-PLC Alliance devotes its efforts to promote the technology through a certification program and logo. The test environment is being updated to offer the current third-generation communication compatibility services as well as upcoming fourth generation interoperability certification services compliant with IEEE 1901-2020.
On March 18, 2021, a webinar*4 on this technology will be held, organized by IEEE SA and HD-PLC Alliance. Also, please visit our renewed website.*5
Related Information:
HD-PLC Alliance members Press Release
[Panasonic Corporation]
Licensing IP Core for Semiconductors Complying with the IEEE 1901–2020 International Standard
https://news.panasonic.com/global/press/data/2021/03/en210316-2/en210316-2.html
[Socionext Inc.]
Socionext Agrees With MIRAIT, MMD, And Nuri Telecom On Next-Generation Long-Distance Power Line Communications For Verification And Social Implementation
https://www.socionext.com/en/pr/sn_pr20210309_01e.pdf
(Note) |
|
*1: |
HD-PLC™: A registered trademark or trademark of Panasonic Corporation in Japan and other countries. |
*2: |
HD-PLC Alliance: Established on September 25, 2007 with the aim to expand the use of High-definition Power Line Communication (HD-PLC) and to ensure communication compatibility. |
*3: |
IEEE Standards Association: Standards association within the Institute of Electrical and Electronics Engineers (IEEE) |
IEEE 1901-2020 standard: https://standards.ieee.org/standard/1901-2020.html |
|
*4: |
IEEE SA and HD-PLC Alliance Webinar March 2021 |
|
Subtitle: Home networking, Industrial and Building automation through HD-PLC (High-Speed Powerline Communication) |
Learn more: https://standards.ieee.org/events/index.html |
|
*5: |
HD-PLC Alliance Homepage: https://hd-plc.org/ |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005273/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom